Skip to main content
. 2010 Mar;95(3):388–397. doi: 10.3324/haematol.2009.016063

Figure 2.

Figure 2.

Effect of treatment with imatinib, nilotinib and transfection with BCR-ABL siRNA or co-treatment of BCR-ABL siRNA with imatinib or nilotinib in tyrosine kinase inhibitor-sensitive (A) and –resistant BCR-ABL oligoclonal cell lines (B: H396P, C: T315I) on MDR1 gene expression. MDR1 gene expression was detected by real time RT-PCR and normalized to GAPDH expression. Control was set at 100%.